Viyash Scientific Q3: Strong EBITDA Growth Offsets Net Profit Decline

2 min read     Updated on 06 Feb 2026, 05:48 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Viyash Scientific delivered mixed Q3 results with strong operational improvements including revenue growth to 8.6B rupees and EBITDA surge of 80.54% to 1.8B rupees, while EBITDA margins expanded significantly to 20.46% from 12.88% YoY. The company reported an exceptional item of 413M rupees and PBT growth to 1.14B rupees, though consolidated net profit declined to 384M rupees from 446M rupees YoY.

powered bylight_fuzz_icon
31851205

*this image is generated using AI for illustrative purposes only.

Viyash Scientific has delivered impressive Q3 results, demonstrating strong operational performance with significant EBITDA growth and margin expansion, alongside revenue growth. The company's profit before tax (PBT) showed remarkable improvement, supported by an exceptional item during the quarter.

Financial Performance Overview

The company's Q3 performance showcases robust operational efficiency improvements, with EBITDA nearly doubling year-over-year and margins expanding substantially. The standout performance includes a significant surge in PBT, reflecting improved profitability metrics at the pre-tax level.

Financial Metric: Q3 Current Year Q3 Previous Year Performance
Consolidated Revenue 8.6B rupees 7.7B rupees Growth
EBITDA 1.8B rupees 997M rupees +80.54%
EBITDA Margin 20.46% 12.88% +757 bps
PBT 1.14B rupees 274M rupees Strong Growth
Consolidated Net Profit 384M rupees 446M rupees Decline
Exceptional Item 413M rupees - One-time Gain

Revenue and Operational Performance

Viyash Scientific demonstrated solid revenue growth in Q3, with consolidated revenue reaching 8.6B rupees compared to 7.7B rupees in the corresponding quarter of the previous year. This year-over-year increase reflects the company's ability to expand its business operations and capture market opportunities during the quarter.

EBITDA and PBT Performance

The standout performance came from the company's EBITDA metrics, with earnings reaching 1.8B rupees in Q3, representing a substantial increase from 997M rupees in the same quarter of the previous year. The EBITDA margin expanded significantly to 20.46% from 12.88% year-over-year, indicating improved operational efficiency and cost management.

The company's profit before tax showed remarkable improvement, reaching 1.14B rupees in Q3 compared to 274M rupees in the same quarter of the previous year, representing substantial growth in pre-tax profitability.

Exceptional Item Impact

Viyash Scientific reported an exceptional item of 413M rupees during Q3, which contributed to the overall financial performance. This one-time item represents a significant component of the quarter's results and provides additional context for understanding the company's financial metrics.

Profitability Analysis

Despite the strong EBITDA performance, revenue growth, and improved PBT, the company's consolidated net profit declined to 384M rupees in Q3, down from 446M rupees in the same quarter of the previous year. This contrast between improved operational metrics and lower net profit, even with the exceptional item, suggests that other factors such as tax expenses may have impacted the final profitability during the reporting period.

like15
dislike

Viyash Scientific Forms Strategic Partnership with Boehringer Ingelheim for Companion Animal Products in India

1 min read     Updated on 22 Jan 2026, 05:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Viyash Scientific has formed a strategic partnership with global pharmaceutical company Boehringer Ingelheim to expand companion animal products in India. The collaboration focuses on growing the veterinary healthcare segment and leverages both companies' expertise to strengthen market presence in India's companion animal products sector.

powered bylight_fuzz_icon
30630108

*this image is generated using AI for illustrative purposes only.

Viyash Scientific has entered into a strategic partnership with Boehringer Ingelheim, a global pharmaceutical company, to expand companion animal products in the Indian market. This collaboration marks a significant business development for the company as it seeks to strengthen its position in the veterinary healthcare sector.

Partnership Details

The partnership focuses specifically on growing the companion animal products segment within India's veterinary market. Boehringer Ingelheim brings extensive global expertise in animal health products to this collaboration.

Partnership Aspect: Details
Partner Company: Boehringer Ingelheim
Focus Area: Companion Animal Products
Target Market: India
Business Objective: Market Growth and Expansion

Strategic Significance

This partnership represents Viyash Scientific's commitment to expanding its veterinary healthcare portfolio. The collaboration with an established global pharmaceutical company demonstrates the company's strategic approach to market development in the companion animal segment.

The partnership is expected to leverage Boehringer Ingelheim's international experience in animal health products while utilizing Viyash Scientific's understanding of the Indian market dynamics.

Market Implications

The collaboration positions both companies to capitalize on opportunities in India's growing companion animal products market. This strategic alliance reflects the increasing focus on veterinary healthcare solutions in the domestic market.

like19
dislike